Intelligence Profile
Clinical Applications
GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is being investigated across several clinical domains, though much of the current evidence comes from preclinical studies with limited human clinical trial data available.
Wound Healing and Skin Regeneration
The primary clinical focus for GHK-Cu appears to be wound healing and skin applications. Currently, there is one active Phase 2 clinical trial (NCT07437586) recruiting participants to evaluate topical GHK-Cu gel for acute skin wound healing, which will provide important human efficacy data.
Preclinical research suggests GHK-Cu may have particular utility in complex wound healing scenarios. Studies have explored its potential in diabetic wound healing, where it may help regulate glucose levels and reverse hypoxia in infected wounds. Research has also investigated its use in radiation-induced skin injury, where it was incorporated into injectable hydrogels designed to provide sequential antioxidant and tissue regeneration therapy.
Aesthetic and Anti-Aging Applications
A completed Phase 4 trial (NCT05932732) examined facial skin quality, hydration, and skin barrier function, though this study appears to have evaluated GHK-Cu as part of combination treatments rather than as a standalone therapy.
The cosmetic and aesthetic medicine literature includes GHK-Cu among therapeutic peptides being investigated for various aesthetic, metabolic, and endocrine conditions, though specific clinical outcomes data in humans remains limited.
Neurological and Aging Research
Emerging preclinical research suggests potential neurological applications, with studies in middle-aged mice showing behavioral improvements when GHK-Cu was administered intraperitoneally or intranasally. However, these findings revealed "divergent hippocampal aging programs," indicating complex and potentially variable effects on brain aging processes.
Current Evidence Limitations
The clinical evidence base for GHK-Cu remains largely preclinical, with most studies conducted in cell cultures, animal models (including C. elegans and mice), or as part of biomaterial research. While the ongoing Phase 2 wound healing trial may provide valuable human efficacy data, clinicians should note that robust clinical evidence in humans is currently limited.
Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Patients considering GHK-Cu therapy should consult with qualified healthcare providers about potential benefits, risks, and appropriate applications for their specific conditions.